Four Decades for Justice
Cravath represented Mylan Inc. in connection with its $1.5 billion 144A/Reg. S senior notes offering. Mylan Inc. is a wholly owned subsidiary of Mylan N.V., a leading global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The transaction closed on April 9, 2018.
The Cravath team included associates Alex M. Dzioba and Justin B. Stein on securities matters, and associate Kiran Sheffrin on tax matters. Jeffrey M. Amico also worked on securities matters.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.